Category Archives: Stem Cell Therapy

Dr Sherif Stem cell therapy on OA
lecture powerpoint.

By: Medical Center

Link:
Dr Sherif Stem cell therapy on OA - Video

DAVIS (CBS13) Researchers at UC Davis say they are one step closer to finding a cure for HIV in a breakthrough study for millions around the world living with the virus.

At 60 years old, Paul Curtis looks like the picture of health.

I exercise, eat well get a lot of rest, he said.

But 30 years ago, Curtis was diagnosed as HIV-positive. Doctors told him he might have a year to live, but hes proven them wrong.

With this disease, its imperative that you take the medications consistently, Curtis said.

He relies on medication daily. At one point he took more than 40 pills a day. And he cant miss a dose.

The virus mutates rapidly when you miss doses, he said.

Hes one of millions worldwide waiting for a cure. Previous studies have come close, but none have proven to fight off the virus with stem cell therapy.

Dr. Joe Anderson says he has developed genetically modified human stem cells, which have resisted infection in mice.

When we infected the mice that had these HIV-resistant that had these HIV-resistant immune cells in them, we saw that HIV infection was blocked, he said.

See original here:
Stem Cell Treatment Has UC Davis A Step Closer To HIV Cure

Live100 Hospitals - Stem Cell Therapy
"We wanted to focus on stem cell after seeing the advantages since the cells were available in the body and they were really doing wonderful research across the world which was really promising...

By: Live100 Hospitals

Follow this link:
Live100 Hospitals - Stem Cell Therapy - Video

UC Davis to test device that offers new approach to obtaining stem cells during surgery

(SACRAMENTO, Calif.) -- A new device that can rapidly concentrate and extract young cells from irrigation fluid used during orthopaedic surgery holds promise for improving the delivery of stem cell therapy in cases of non-healing fractures. UC Davis surgeons plan to launch a "proof-of-concept" clinical trial to test the safety and efficacy of the device in the coming months.

"People come to me after suffering for six months or more with a non-healing bone fracture, often after multiple surgeries, infections and hospitalizations," said Mark Lee, associate professor of orthopaedic surgery, who will be principal investigator of the upcoming clinical trial. "Stem cell therapy for these patients can be miraculous, and it is exciting to explore an important new way to improve on its delivery."

About 6 million people suffer fractures each year in North America, according to the American Academy of Orthopaedic Surgeons. Five to 10 percent of those cases involve patients who either have delayed healing or fractures that do not heal. The problem is especially troubling for the elderly because a non-healing fracture significantly reduces a person's function, mobility and quality of life.

Stem cells - early cells that can differentiate into a variety of cell types - have been used for several years to successfully treat bone fractures that otherwise have proven resistant to healing. Applied directly to a wound site, stem cells help with new bone growth, filling gaps and allowing healing and restoration of function. However, obtaining stem cells ready to be delivered to a patient can be problematic. The cells ideally come from a patient's own bone marrow, eliminating the need to use embryonic stem cells or find a matched donor.

But the traditional way of obtaining these autologous stem cells - that is, stem cells from the same person who will receive them - requires retrieving the cells from a patient's bone marrow, a painful surgical procedure involving general anesthesia, a large needle into the hip and about a week of recovery.

In addition, the cells destined to become healing blood vessels must be specially isolated from the bone marrow before they are ready to be transplanted back into the patient, a process that takes so long it requires a second surgery.

The device Lee and his UC Davis colleagues will be testing processes the "wastewater" fluid obtained during an orthopaedic procedure, which makes use of a reamer-irrigator-aspirator (RIA) system to enlarge a patient's femur or tibia by high-speed drilling, while continuously cooling the area with water. In the process, bone marrow cells and tiny bone fragments are aspirated and collected in a filter to transplant back into the patient. Normally, the wastewater is discarded.

Although the RIA system filter captures the patient's own bone and bone marrow for use in a bone graft or fusion, researchers found that the discarded effluent contained abundant mesenchymal stem cells as well as hematopoietic and endothelial progenitor cells, which have the potential to make new blood vessels, and potent growth factors important for signaling cells for wound healing and regeneration. The problem, however, was that the RIA system wastewater was too diluted to be useful.

Now, working with a device developed by SynGen Inc., a Sacramento-based biotech company specializing in regenerative medicine applications, the UC Davis orthopaedic team will be able to take the wastewater and spin it down to isolate the valuable stem cell components. About the size of a household coffee maker, the device will be used in the operating room to rapidly produce a concentration of stem cells that can be delivered to a patient's non-union fracture during a single surgery.

Visit link:
Treating non-healing bone fractures with stem cells

The new clinic claims its stem-cell treatment can benefit those suffering from emphysema, chronic bronchitis, pulmonary fibrosis and most forms of lung disease.(Photo: Getty Images/iStockphoto)

The Lung Institute, a national clinic that uses adult stem cells extracted from fat and blood to treat pulmonary conditions, is set to open next month in Scottsdale, the for-profit company's first location in the western United States.

The new clinic claims its treatment can benefit those suffering from emphysema, chronic bronchitis, pulmonary fibrosis and most forms of lung disease.

Such stem-cell therapy is part of a growing trend particularly among affluent Americans who can afford it to treat a variety of health problems with cells taken from their own bodies.

The industry remains largely controversial, with plenty of doubters and detractors who say the science is unproven and potentially dangerous.

The International Society for Stem Cell Research, an independent non-profit organization based in Illinois, cautions against the potential risk of some treatments, which it says could cause cancer or result in infection from the procedure itself. The group suggests patients speak with their doctor about the potential benefits or risks of stem-cell therapy.

For its part, Lung Institute says the treatment helps fight lung conditions including chronic obstructive pulmonary disease, one of the world's leading killers. Cells extracted from one organ can create healthy tissue in another organ, the company claims.

The therapy is provided as an outpatient service, and patients can have cells drawn, isolated and planted in the affected area all in the same day. The clinic does not use embryonic, umbilical cord or donor stem cells.

Lung Institute, a clinic that uses stem cells to treat pulmonary conditions, is set to open its first West Coast location in Scottsdale in February 2015.(Photo: Courtesy of Lung Institute)

Patients typically visit the clinic for a few hours over three consecutive days. The treatment seeks to slow disease progression, calm inflammation or repair damaged tissue.

Go here to see the original:
Stem-cell therapy clinic to open in Valley

A therapy for Parkinson's disease from Carlsbad's International Stem Cell Corp. is expected to get approval for testing in Australia as soon as February, the company said this week.

The publicly traded company has grown neural stem cells, which can mature into cells making the neurotransmitter dopamine, deficient in Parkinson's. The company plans to implant these stem cells into the the brains of Parkinson's patients, restoring dopamine production and normal movement in the patients.

If approved, the trial will be the first test of therapy with the company's cells, derived from unfertilized, or parthenogenetic human egg cells. The cells, which in theory can produce nearly all types of cells found in the body, are grown into neural stem cells. These cells will be implanted and mature in place.

Parthenogenetic cells have much the same potential as embryonic stem cells without the ethical objections some have, says International Stem Cell, which has 38 employees. In addition, these parthenogenetic stem cells are less likely to provoke an immune reaction, the company says.

International Stem Cell Corp. chose Australia for its first trial because its regulatory agency is more "interactive" than the U.S. Food and Drug Administration, said Simon Craw, executive vice president for business development. The FDA is inclined to give yes-or-no answers for proposed cell-based treatments, Craw said. In addition, patient recruitment takes place more slowly, which delays trial completion. The FDA does this for safety reasons.

Simon Craw / International Stem Cell Corp.

The Australian agency helps guide companies through the application process, Craw said in an interview Wednesday at Biotech Showcase, an annual life science conference in San Francisco. Craw also gave a company presentation on Tuesday at the conference.

"We're in the process of submitting the (application)," to Australian regulators, Craw said. "We're going back and forth with them right now. We expect to hear back from them by the end of February."

The trial will primarily assess safety, but also look for evidence of efficacy, Craw said.

The trial will take place at Royal Melbourne Hospital, Craw said. The hospital is headquartered in Parkville, in the state of Victoria. The principal investigator, Dr. Andrew Evans, will recruit patients from his own practice.

See more here:
Parkinson's stem cell trial approaches

Enlarge Image

Winnipeg researcher Doug Broeska previously ran a lumber business. (REGENETEK.COM)

Enlarge Image

Regenetek is located on Chevrier Boulevard, but its stem-cell study is being conducted at a hospital in India. The study is not listed on any clinical-trial registry. (PHIL HOSSACK / WINNIPEG FREE PRESS )

The hope of dancing at her sons summertime wedding led Sharon Nordstrom to pay $38,000 for a treatment she hoped would keep her multiple-sclerosis symptoms at bay.

That money paid for what she hoped would be a life-changing stem-cell procedure at a hospital in Pune, India. It was part of what she, and nearly 70 other patients from Manitoba and from as far away as Australia, believed was a clinical study helmed by a brilliant Winnipeg medical researcher with a PhD, who said the procedure could stop MS in its tracks.

Soon after her return in May, Nordstrom began to uncover troubling facts. Doug Broeska, whom patients reverently call "Dr. Doug," has no recognized medical credentials. Regenetek Research, his company based out of a spartan office on Chevrier Boulevard, boasted credentials and positive medical results that didnt add up. Patients who were once ardent supporters were attacked as saboteurs or shills for "Big Pharma" and threatened with removal from the study after they asked questions.

A Free Press investigation has found Broeska fabricated his credentials, including his PhD, and overstated the effects of the stem-cell treatment, for which he often charged desperately ill people $45,000. Four patients spoke to the Free Press on the record, saying they got no benefit from the treatment, got none of the followup common in clinical trials such as MRIs or physical acuity tests and believe they are victims of fraud.

Patients, doctors in India and now Canadian officials are questioning the claims of Winnipeg researcher Doug Broeska and his $45,000 stem-cell therapy for MS sufferers.

At least two of Regeneteks former patients have complained to the RCMP, and sources say the Canada Revenue Agency is investigating, though CRA officials would not confirm that. Last week, Regeneteks website, Broeskas LinkedIn page and a "patient-run" Facebook group were taken down.

The rest is here:
City man who ran stem-cell trial for MS patients fabricated credentials, overstated results

Stem Cell Therapy: A cure for Diabetes | PlacidWay
http://tiny.cc/DiabetesCure2015 Diabetes treatment can consist of numerous elements, consisting of standard medications, alternative medication, and natural treatments. Alternative therapies...

By: Robert Esser

Continued here:
Stem Cell Therapy: A cure for Diabetes | PlacidWay - Video